The relationship between cardiometabolic and hemostatic variables: influence of race

Metabolism: Clinical and Experimental

Volumn 57, Issue 2, 2008, Pages 200-206

  Perry, Arlette ^a   Wang, Xuewen ^b   Goldberg, Ronald ^c   Ross, Robert ^d   Jackson, Loreto ^e  

^a UNIVERSITY OF MIAMI   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e CLEMSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; INSULIN; PLASMA ACTIVATOR INHIBITOR 1; PLASMA PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART MUSCLE METABOLISM; HEMOSTASIS; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; OBESITY; PRIORITY JOURNAL; PROTEIN INTERACTION; RACE DIFFERENCE; WAIST HIP RATIO;

ADULT; AFRICAN AMERICANS; APOLIPOPROTEINS B; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FIBRINOGEN; HUMANS; INSULIN; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGRESSION ANALYSIS; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 38049069281     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.09.001     Document Type: Article

References (33)

1. Davies M.J., and Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 310 (1984) 1137-1140
2. Juhan-Vague I. Haemostatic parameters and vascular risk. Atherosclerosis 124 (1996) S49-S55
3. Fuster V., Badimon L., Badimon J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326 (1992) 242-250
4. Juhan-Vague I., Alessi M.C., and Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34 (1991) 457-462
5. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., and deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology program (SHEEP) study. Arterioscler Thromb Vasc Biol 20 (2000) 2019-2023
6. Potter van Loon B.J., Kluft G., Radder J.K., Blankenstein M.A., and Meinders A.E. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance. Metabolism 42 (1993) 945-949
7. Colleen D., and Lignin H.R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78 (1991) 3114-3124
8. Folsom A.R., Pankow J.S., Williams R.R., Evans G.W., Province M.A., and Eckfeldt J.H. Fibrinogen plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb Haemost 79 (1998) 400-404
9. Festa A., D'Agostino Jr. R., Tracy R.P., and Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51 (2002) 1131-1137
10. Haffner S.M. Insulin resistance, inflammation and the prediabetic state. Am J Cardiol 92 suppl (2003) 18J-26J
11. Folsom A.R., Wu K.K., Davis C.E., Conlan M.G., Sorlie P.D., and Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 91 (1991) 191-205
12. Paffenbarger Jr. R.S., Blair S.N., Lee I.M., and Hyde R.T. Measurement of physical activity to assess health effects in free-living populations. Med Sci Sports Exerc 25 (1993) 60-70
13. Rosmond R., Lapidus L., and Bjorntorp P. The influence of occupation and social factors on obesity and body fat distribution in middle-aged men. Int J Obes 20 (1996) 599-607
14. Brantley P.J., Dietz L.S., McKnight G.T., Jones G.N., and Tulley R. Convergence between the daily stress and endocrine measures of stress. J Consult Clin Psychol 56 (1998) 549-551
15. World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee (1995), World Health Organization, Geneva
16. Manual of laboratory operations lipid research clinic program: lipid and lipoprotein analysis (1974), DHEW publ, Washington, DC
17. Warnick G.R., and Albers J.J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 19 (1978) 76
18. Gidez L.I., Miller G.J., Burnstein M., Slagle S., and Eder H.A. Separation and quantification of subclasses of human plasma high-density lipoproteins by a simple precipitation procedure. J Lipid Res 23 (1982) 1206-1223
19. McGowan M.W., Artiss J.D., Strandbergh D.R., and Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 29 (1983) 538-542
20. Friedwald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
21. Krauss R.M., and Burke D.J. Identification of multiple subclasses of plasma low-density lipoproteins in normal humans. J Lipid Res 23 (1998) 97-104
22. Haffner S.M., Miettinen H., and Stern M.P. The homeostasis model in the San Antonio Heart Study. Diabetes Care 20 (1997) 1087-1092
23. SPSS for Windows, release 10.1 (2000), SPSS Inc, Chicago (Ill)
24. Bostom A.G., Shemin D., Lapane K.L., et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 125 (1996) 91-101
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 85 (2001) 2486-2497
26. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., and Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96 (1997) 1102-1108
27. Thögersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
28. Conway J.M., Yanovski S.Z., and Hubbard V.S. Visceral adipose tissue differences in black and white women. Am J Clin Nutr 61 (1995) 765-771
29. Darga L.L., Holden J.H., Olsen S.M., and Lucas C.P. Comparison of cardiovascular risk factors in obese blacks and whites. Obes Res 2 (1994) 239-245
30. Brancati F.L., Kao W.H.L., Folsom A.R., Watson R.L., and Szklo M. Incident type 2 diabetes mellitus in African American and white adults. JAMA 283 (2000) 2253-2259
31. Vague P., Juhan-Vague I., Aillaud M.F., et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35 (1986) 250-253
32. Alesssi M.C., Peiretti F., Morange P., Henry M., Nalbone G., and Juhan-Vague I. Production of plasminogen activator inhibitor by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 46 (1997) 860-867
33. Juhan-Vague I., Morange P., and Alessi M.C. Fibrinolytic function and coronary risk. Curr Cardiol Rep 1 (1999) 119-124